How is Cardiotoxicity managed in patients receiving Anthracyclines?
Cardiotoxicity management involves regular monitoring of cardiac function, typically using echocardiograms or MUGA scans. Dose adjustments and the use of cardioprotective agents such as dexrazoxane can mitigate risks. In some cases, liposomal formulations of anthracyclines are used to reduce cardiac exposure.
